Clinical Trial Update: Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study [Phase 2]

View source ↗

Summary

Phase 2 trial investigating induction with a Bruton tyrosine kinase inhibitor and rituximab followed by glofitamab consolidation in high-risk untreated mantle c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• BTKi
• Glofitamab (glofitamab)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase 2 Study, MCL | Phase 2 | Status: RECRUITING